13737-35-4

Basic information

• Product Name: Benzeneacetic acid, 2-(bromomethyl)-
• CAS NO: 13737-35-4
• Molecular Formula: C9H9BrO2
• Molecular Weight: 229.073
• Mol File: 13737-35-4.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, 2-(bromomethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 2-(bromomethyl)-(13737-35-4)
• EPA Substance Registry System: Benzeneacetic acid, 2-(bromomethyl)-(13737-35-4)

Safety Data

• Hazardous Substances Data: 13737-35-4(Hazardous Substances Data)

Usage

General Description

Benzeneacetic acid, 2-(bromomethyl)-, also known as α-bromo-2-phenylacetic acid, is a chemical compound with the molecular formula C9H9BrO2. It is a white to light beige crystalline powder that is soluble in polar solvents such as water, ethanol, and acetone. Benzeneacetic acid, 2-(bromomethyl)- is commonly used in the synthesis of pharmaceuticals, especially in the formation of α-bromo-2-phenylacetic acid-derived drugs. It is also utilized as an intermediate in the production of perfumes, dyes, and other organic compounds. However, its use and handling require caution, as it is considered hazardous and can cause skin and eye irritation, as well as respiratory issues if inhaled.

Upstream product

• 644-36-0 o-methylphenylacetic acid 
• 34241-39-9 azobisisobutyronitrile 
• 4385-35-7 isochroman-3-one 
• 22364-68-7 2-tolylmethylnitrile 

Downstream Products

• 13737-37-6 methyl 2-[2-(bromomethyl)phenyl]acetate 
• 913394-35-1 (2-mercaptomethyl-phenyl)-acetic acid 
• 39113-02-5 2-amino-1,4-dihydroisoquinolin-3(2H)-one 
• 138813-29-3 2-<<5-<3-(quinolin-2-ylmethoxy)phenyl>-2H-tetrazol-2-yl>methyl>benzeneacetic acid methyl ester 
• 138786-42-2 2-<<5-<3-(quinolin-2-ylmethoxy)phenyl>-2H-tetrazol-2-yl>methyl>benzeneacetic acid 
• 138786-47-7 2-<<5-<3-(2-quinolin-2-ylethenyl)phenyl>-2H-tetrazol-2-yl>methyl>benzeneacetic acid methyl ester 
• 138786-45-5 (2-{5-[3-((E)-2-Quinolin-2-yl-vinyl)-phenyl]-tetrazol-2-ylmethyl}-phenyl)-acetic acid 
• 138786-44-4 methyl <2-(iodomethyl)phenyl>acetate 
• 39113-25-2 2-(N'-phenylureido)-1,4-dihydroisoquinolin-3(2H)-one 
• 39113-18-3 3,4-Dichloro-N-(3-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-benzamide 
• 39113-07-0 2-{[1-(3,4-Dichloro-phenyl)-meth-(Z)-ylidene]-amino}-1,4-dihydro-2H-isoquinolin-3-one 
• 39113-15-0 N-(3-oxo-3,4-dihydroisoquinolin-2(1H)-yl)benzamide 
• 39113-05-8 2-{[1-Phenyl-meth-(Z)-ylidene]-amino}-1,4-dihydro-2H-isoquinolin-3-one 
• 39113-24-1 2-ureido-1,4-dihydroisoquinolin-3(2H)-one 

Relevant articles and documents

Novel imidazobenzazepine derivatives as dual H1/5-HT 2A antagonists for the treatment of sleep disorders

A novel imidazobenzazepine template (5a) with potent dual H 1/5-HT2A antagonist activity was identified. Application of a zwitterionic approach to this poorly selective and poorly developable starting point successfully delivered a class of high quality leads, 3-[4-(3-R1-2-R-5H-imidazo[1,2-b][2]benzazepin-11-yl)-1-piperazinyl]- 2,2-dimethylpropanoic acids (e.g., 9, 19, 20, and 21), characterized by potent and balanced H1/5-HT2A receptor antagonist activities and good developability profiles.

Synthesis and structure activity relationships of novel non-peptidic metallo-aminopeptidase inhibitors

Racemic derivatives of 3-amino-2-tetralone were synthesised and evaluated for their ability to inhibit metallo-aminopeptidase activities. New compounds substituted in position 2 by methyl ketone, substituted oximes or hydroxamic acids as well as heterocyclic derivatives were evaluated against representative members of zinc-dependent aminopeptidases: leucine aminopeptidase (E.C. 3.4.11.1), aminopeptidase-N (E.C. 3.4.11.2), Aeromonas proteolytica aminopeptidase (E.C. 3.4.11.10), and the aminopeptidase activity of leukotriene A4 hydrolase (E.C. 3.3.2.6). Several compounds showed Ki values in the low micromolar range against the 'one-zinc' aminopeptidases, while most of them were rather poor inhibitors of the 'two-zinc' enzymes. This interesting selectivity profile may guide the design of new, specific inhibitors of target mammalian aminopeptidases with one active site zinc.

Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position

Thrombin inhibitors incorporating o-aminoalkylbenzylamides in the P1 position were designed, synthesized and found to have enhanced potency and selectivity in several different structural classes. X-ray crystallographic analysis of compound 24 bound in the α-thrombin-hirugen complex provides an explanation for these unanticipated results.